In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1
- PMID: 32017579
- DOI: 10.1021/acs.molpharmaceut.9b01121
In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1
Abstract
Clinical trials have demonstrated partial protection against HIV-1 infection by vaginal microbicide formulations based on antiretroviral (ARV) drugs. Improved formulations that will maintain sustained drug concentrations at viral target sites in the cervicovaginal mucosa are needed. We have previously demonstrated that treatment of cervicovaginal cell lines with ARV drugs can alter gene expression of drug transporters, suggesting that the mucosal disposition of ARV drugs delivered vaginally can be modulated by drug transporters. This study aimed to investigate in vivo modulation of drug transporter expression in a nonhuman primate model by tenofovir and darunavir released from film formulations. Cervicovaginal tissues were collected from drug-naïve macaques and from macaques vaginally treated with film formulations of tenofovir or darunavir. Drug release in vaginal fluid as well as drug absorption in cervicovaginal tissues and lymph nodes were verified by mass spectrometry. The effects of exposure to drugs on the expression of transporters relevant to ARV drugs were evaluated by quantitative PCR. We showed expression in cervicovaginal tissue of drug-naïve macaques of transporters important for distribution of ARV drugs, albeit at lower levels compared to human tissue for key transporters including P-glycoprotein. Concentrations of tenofovir and darunavir well above the EC50 values determined in vitro were detected in vaginal fluid and vaginal tissues of macaques treated with drug-dissolving films over 24 h and were also comparable to those shown previously to modulate drug transporter expression. Accordingly, Multidrug Resistance associated Protein 2 (MRP2) in cervicovaginal tissue was upregulated by both tenofovir and darunavir. The two drugs also differentially induced and/or inhibited expression of key uptake transporters for reverse transcriptase inhibitors and protease inhibitors. The lower expression of key transporters in macaques may result in increased retention of ARV drugs at the simian cervicovaginal mucosa compared to the human mucosa and has implications for translation of preclinical data. Modulation of drug transporter expression by tenofovir and darunavir points to the potential benefit of MRP2 inhibition to increase ARV drug penetration through the cervicovaginal epithelium.
Keywords: darunavir; macaques; microbicides; multidrug resistance associated protein; tenofovir; vagina.
Similar articles
-
Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.PLoS One. 2015 Jun 23;10(6):e0131405. doi: 10.1371/journal.pone.0131405. eCollection 2015. PLoS One. 2015. PMID: 26102284 Free PMC article.
-
Expression, regulation, and function of drug transporters in cervicovaginal tissues of a mouse model used for microbicide testing.Biochem Pharmacol. 2016 Sep 15;116:162-75. doi: 10.1016/j.bcp.2016.07.009. Epub 2016 Jul 21. Biochem Pharmacol. 2016. PMID: 27453435 Free PMC article.
-
Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.PLoS Med. 2018 Sep 28;15(9):e1002655. doi: 10.1371/journal.pmed.1002655. eCollection 2018 Sep. PLoS Med. 2018. PMID: 30265679 Free PMC article. Clinical Trial.
-
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.Infection. 2018 Oct;46(5):599-605. doi: 10.1007/s15010-018-1171-z. Epub 2018 Jun 30. Infection. 2018. PMID: 29961209 Review.
-
Clinical development of microbicides for the prevention of HIV infection.Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374. Curr Pharm Des. 2004. PMID: 14754390 Review.
Cited by
-
High Preventive Effect of G2-S16 Anionic Carbosilane Dendrimer against Sexually Transmitted HSV-2 Infection.Molecules. 2020 Jun 28;25(13):2965. doi: 10.3390/molecules25132965. Molecules. 2020. PMID: 32605185 Free PMC article. Review.
-
Drug transporter mRNA expression and genital inflammation in South African women on oral pre-exposure prophylaxis (PrEP).AIDS Res Ther. 2025 Feb 15;22(1):18. doi: 10.1186/s12981-025-00713-z. AIDS Res Ther. 2025. PMID: 39955595 Free PMC article.
-
The ex vivo pharmacology of HIV-1 antiretrovirals differs between macaques and humans.iScience. 2022 May 16;25(6):104409. doi: 10.1016/j.isci.2022.104409. eCollection 2022 Jun 17. iScience. 2022. PMID: 35663021 Free PMC article.
-
The Potential of Films as Transmucosal Drug Delivery Systems.Pharmaceutics. 2023 Nov 4;15(11):2583. doi: 10.3390/pharmaceutics15112583. Pharmaceutics. 2023. PMID: 38004562 Free PMC article. Review.
-
Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model.Pharmaceutics. 2022 Sep 13;14(9):1938. doi: 10.3390/pharmaceutics14091938. Pharmaceutics. 2022. PMID: 36145684 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical